Hexamethylmelamine in platinum-resistant ovarian cancer: How active?
- 31 December 1992
- journal article
- editorial
- Published by Elsevier in Gynecologic Oncology
- Vol. 47 (3) , 279-281
- https://doi.org/10.1016/0090-8258(92)90126-4
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancerGynecologic Oncology, 1992
- Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferonGynecologic Oncology, 1992
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testingInternational Journal of Gynecologic Cancer, 1991
- Hexamethylmelamine as a single second-line agent in ovarian cancerGynecologic Oncology, 1990
- Role of Hexamethylmelamine in the Treatment of Ovarian Cancer: Where is the Needle in the Haystack?JNCI Journal of the National Cancer Institute, 1988
- Carboplatin: current status and future prospectsCancer Treatment Reviews, 1988
- Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapyGynecologic Oncology, 1987
- Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapyGynecologic Oncology, 1984
- Hexamethylmelamine in alkylating agent-resistant ovarian carcinomaCancer, 1978